N. Snelder

发表

Characterisation of the pharmacokinetics of ethinylestradiol and drospirenone in extended-cycle regimens: population pharmacokinetic analysis from a randomised Phase III study

S. Reif, N. Snelder, H. Blode, 2013, Journal of Family Planning and Reproductive Health Care.

Mechanism-based modeling of the effect of a novel inhibitor of vascular adhesion protein-1 on albuminuria and renal function markers in patients with diabetic kidney disease

T. Larsson, A. García-Hernandez, S. Hoefman, 2020, Journal of pharmacokinetics and pharmacodynamics.

Population pharmacokinetics and pharmacodynamics of a novel vascular adhesion protein-1 inhibitor using a multiple-target mediated drug disposition model

T. Larsson, A. García-Hernandez, S. Hoefman, 2020, Journal of pharmacokinetics and pharmacodynamics.

A novel integrated QSP model of in vivo human glucose regulation to support the development of a glucagon/GLP‐1 dual agonist

E. Sijbrands, P. Vicini, S. Hoefman, 2021, CPT: pharmacometrics & systems pharmacology.

Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event Analysis

T. Eissing, R. Heinig, J. Lippert, 2021, Clinical Pharmacokinetics.

Population Pharmacokinetic and Exposure–Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease

B. Ploeger, T. Eissing, J. Lippert, 2019, Clinical Pharmacokinetics.

Dose–Exposure–Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKD

T. Eissing, H. Heerspink, J. Lippert, 2022, Clinical Pharmacokinetics.

A novel cardiovascular systems model to quantify drugs effects on the inter‐relationship between contractility and other hemodynamic variables

Eric I. Rossman, P. H. van der Graaf, H. Taghvafard, 2022, CPT: pharmacometrics & systems pharmacology.

Dose–Exposure–Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKD

T. Eissing, H. Heerspink, J. Lippert, 2022, Clinical Pharmacokinetics.

Drug effects on the CVS in conscious rats: separating cardiac output into heart rate and stroke volume using PKPD modelling

B. Ploeger, M. Danhof, D. Stanski, 2014, British journal of pharmacology.

PK/PD modeling of FXI antisense oligonucleotides to bridge the dose‐FXI activity relation from healthy volunteers to end‐stage renal disease patients

S. Bhanot, R. Yu, R. Geary, 2021, CPT: pharmacometrics & systems pharmacology.

Pharmacokinetic–Pharmacodynamic Modeling of the Antihypertensive Effect of Eprosartan in Black and White Hypertensive Patients

B. Ploeger, O. Ackaert, R. Mathôt, 2013, Clinical Pharmacokinetics.

A population K-PD model analysis of long-term testosterone inhibition in prostate cancer patients undergoing intermittent androgen deprivation therapy

J. DeJongh, M. Ahsman, N. Snelder, 2021, Journal of Pharmacokinetics and Pharmacodynamics.

Population pharmacokinetic–pharmacodynamic modelling of the relationship between testosterone and prostate specific antigen in patients with prostate cancer during treatment with leuprorelin

N. Wood, M. Hibberd, G. Scott, 2019, British journal of clinical pharmacology.

Nonlinear mixed effects modeling of the diurnal blood pressure profile in a multiracial population.

B. Ploeger, G. V. van Montfrans, O. Ackaert, 2013, American journal of hypertension.

Characterization and Prediction of Cardiovascular Effects of Fingolimod and Siponimod Using a Systems Pharmacology Modeling Approach

B. Ploeger, M. Danhof, D. Stanski, 2017, The Journal of Pharmacology and Experimental Therapeutics.

Translational Pharmacokinetic Modeling of Fingolimod (FTY720) as a Paradigm Compound Subject to Sphingosine Kinase-Mediated Phosphorylation

B. Ploeger, M. Danhof, D. Stanski, 2014, Drug Metabolism and Disposition.

Prediction of attack frequency in migraine : a Markov approach

M. Danhof, N. Snelder, H. Maas, 2007 .

Prediction of Attack Frequency in Migraine Treatment

M. Danhof, O. Della Pasqua, N. Snelder, 2008, Cephalalgia : an international journal of headache.

Finerenone Dose–Exposure–Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria

T. Eissing, J. Lippert, S. Goulooze, 2021, Clinical Pharmacokinetics.

Towards predictive cardiovascular safety : a systems pharmacology approach

N. Snelder, 2014 .

PKPD modelling of the interrelationship between mean arterial BP, cardiac output and total peripheral resistance in conscious rats

M. Danhof, B. A. Ploeger, D. Rigel, 2013, British journal of pharmacology.

Evaluation of a Cardiovascular Systems Model for Design and Analysis of Hemodynamic Safety Studies

Tingjie Guo, N. Snelder, Yueqiao Fu, 2023, Pharmaceutics.

Estimation of binding rate constants using a simultaneous mixed‐effects method: application to monoamine transporter reuptake inhibitor reboxetine

B. Ploeger, N. Benson, R. Butt, 2010, British journal of pharmacology.